RVNC’s pro forma cash balance at 12/31/17=$289.3M. This figure consists of: $264.3M of net current assets on the 12/31/17 balance sheet (https://www.sec.gov/Archives/edgar/data/1479290/000147929018000038/rvnc1231201710k.htm#s4BDE5FBFF06F5892BCA0699CB0E34186 ); and $25M due from MYL pursuant to the companies’ Botox-biosimilar collaboration announced on 2/28/18 (#msg-138919580).